374 related articles for article (PubMed ID: 37627125)
1. Exploring Opportunities to Enhance the Screening and Surveillance of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease (NAFLD) through Risk Stratification Algorithms Incorporating Ultrasound Elastography.
Taru MG; Lupsor-Platon M
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627125
[TBL] [Abstract][Full Text] [Related]
2. Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease.
Seif El Dahan K; Daher D; Singal AG
Clin Mol Hepatol; 2023 Feb; 29(Suppl):S207-S219. PubMed ID: 36103899
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: A Step Forward for Better Evaluation Using Ultrasound Elastography.
Lupsor-Platon M; Serban T; Silion AI; Tirpe A; Florea M
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32998257
[TBL] [Abstract][Full Text] [Related]
4. Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?
Plaz Torres MC; Bodini G; Furnari M; Marabotto E; Zentilin P; Strazzabosco M; Giannini EG
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32486355
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: The Prognostic Role of Liver Stiffness Measurement.
Cerrito L; Mignini I; Ainora ME; Mosoni C; Gasbarrini A; Zocco MA
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765595
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology and risk-stratification of NAFLD-associated HCC.
Ioannou GN
J Hepatol; 2021 Dec; 75(6):1476-1484. PubMed ID: 34453963
[TBL] [Abstract][Full Text] [Related]
7. How to Identify Advanced Fibrosis in Adult Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Using Ultrasound Elastography-A Review of the Literature and Proposed Multistep Approach.
Taru MG; Neamti L; Taru V; Procopciuc LM; Procopet B; Lupsor-Platon M
Diagnostics (Basel); 2023 Feb; 13(4):. PubMed ID: 36832276
[TBL] [Abstract][Full Text] [Related]
8. Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma.
Said A; Ghufran A
World J Clin Oncol; 2017 Dec; 8(6):429-436. PubMed ID: 29291167
[TBL] [Abstract][Full Text] [Related]
9. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.
Ioannou GN; Green P; Kerr KF; Berry K
J Hepatol; 2019 Sep; 71(3):523-533. PubMed ID: 31145929
[TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
11. Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease.
Tovoli F; Ferri S; Piscaglia F
Curr Pharm Des; 2020; 26(32):3909-3914. PubMed ID: 32348210
[TBL] [Abstract][Full Text] [Related]
12. Advances in ultrasound elastography for nonalcoholic fatty liver disease.
Yoneda M; Honda Y; Nogami A; Imajo K; Nakajima A
J Med Ultrason (2001); 2020 Oct; 47(4):521-533. PubMed ID: 32748075
[TBL] [Abstract][Full Text] [Related]
13. Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link.
Chrysavgis L; Giannakodimos I; Diamantopoulou P; Cholongitas E
World J Gastroenterol; 2022 Jan; 28(3):310-331. PubMed ID: 35110952
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
Perumpail RB; Wong RJ; Ahmed A; Harrison SA
Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
[TBL] [Abstract][Full Text] [Related]
15. Contribution of organokines in the development of NAFLD/NASH associated hepatocellular carcinoma.
Vachher M; Bansal S; Kumar B; Yadav S; Arora T; Wali NM; Burman A
J Cell Biochem; 2022 Oct; 123(10):1553-1584. PubMed ID: 35818831
[TBL] [Abstract][Full Text] [Related]
16. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
17. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.
Liu YL; Patman GL; Leathart JB; Piguet AC; Burt AD; Dufour JF; Day CP; Daly AK; Reeves HL; Anstee QM
J Hepatol; 2014 Jul; 61(1):75-81. PubMed ID: 24607626
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma in patients with metabolic dysfunction-associated fatty liver disease: Can we stratify at-risk populations?
Fassio E; Barreyro FJ; Pérez MS; Dávila D; Landeira G; Gualano G; Ruffillo G
World J Hepatol; 2022 Feb; 14(2):354-371. PubMed ID: 35317172
[TBL] [Abstract][Full Text] [Related]
19. NAFLD and NAFLD-related HCC in Asia: Burden and Surveillance.
Koh JH; Wang M; Suzuki H; Muthiah M; Ng CH; Huang DQ
J Clin Exp Hepatol; 2024; 14(1):101213. PubMed ID: 38076360
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology of non-alcoholic fatty liver disease-related hepatocellular carcinoma and its implications.
Wong SW; Ting YW; Chan WK
JGH Open; 2018 Oct; 2(5):235-241. PubMed ID: 30483595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
